Conversion from Calcineurin Inhibitor to Sirolimus for Renal Function Deterioration in Kidney Allograft Recipients

Archives of Medical Research

Volumn 37, Issue 5, 2006, Pages 635-638

  Martínez Mier, Gustavo ^a   Méndez López, Marco Tulio ^a,b   Estrada Oros, Jorge ^a,b   Budar Fernandez, Luis F ^a,b   Soto González, Juan I ^a,b   Méndez Machado, Gustavo F ^b,c   Viñas Dozal, Julio Cesar ^a  

^a Universidad Cristobal Colon   (Mexico)

^b Department of Nephrology ^*  (Mexico)

^c IMSS Adolfo Ruiz Cortines National Medical Center   (Mexico)

Author keywords

Calcineurin nephrotoxicity; Immunosuppression; Kidney transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CALCIUM; CREATININE; CYCLOSPORIN A; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POTASSIUM; PREDNISONE; RAPAMYCIN; STEROID; ZAVEN;

ACUTE TOXICITY; ADULT; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; FEMALE; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; HIRSUTISM; HUMAN; HYPERPLASIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ATROPHY; KIDNEY TUBULE DISORDER; LEUKOPENIA; LIVER TOXICITY; MALE; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; CALCINEURIN; CALCIUM; CREATININE; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MONITORING, PHYSIOLOGIC; POTASSIUM; RETROSPECTIVE STUDIES; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UREA;

EID: 33646891563     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2005.12.003     Document Type: Article

References (18)

1. Cecka J, ed. The UNOS Scientific Renal Transplant Registry. Clinical Transplants (published annually by the UCLA Tissue Typing Laboratory);1996:1-14.
2. McKane W., Kanganas C., Preston R., Cairns T., Hakim N., Palmer A., et al. Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil. Transplant Proc 33 (2001) 1224-1225
3. Sehgal S.N., Bake H., and Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 28 (1975) 727-732
4. Kahan B.D., Julian B.A., Pescovitz M.D., Vanrenterghem Y., and Neylan J. Sirolimus reduces the incident of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune study group. Transplantation 68 (1999) 1526-1532
5. Johnson R.W.G., Kreis H., Oberhauer R., Brattstrom C., Claesson K., and Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001 (2001) 777-786
6. Hrick D.E., and for the Rapamune Renal Function Study Group. Improved renal function with cyclosporine elimination in sirolimus treated renal transplant recipients. Am J Transplant 1 suppl 1 (2001) 149
7. Kreis H., Oberhauer R., Campistol J.M., Mathew T., Daloze P., Schena F.P., et al. Long-term benefits with sirolimus based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15 (2004) 809-817
8. Mota A., Arias M., Taskinen E.I., Paavonen T., Brault Y., Legendre C., et al. Sirolimus based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4 (2004) 953-961
9. Groth C.G., Backman L., Morales J.M., Calne R., Kreis H., Lang P., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 67 (1999) 1036-1042
10. Kreis H., Cisterne J.M., Land W., Wrammer L., Squifflet J.P., Abramowicz D., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69 (2000) 1252-1260
11. Flechner S.M., Goldfarb D., Modlin C., Feng J., Krishnamurthi V., Mastroianni B., et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective randomized trial of sirolimus versus cyclosporine. Transplantation 74 (2002) 1070-1076
12. Dominguez J., Mahalati K., Kiberd B., McAllister V.C., and MacDonald A.S. Conversion to rapamycin immunosuppression in renal transplant recipients: reports of an initial experience. Transplantation 70 (2000) 1244-1247
13. Diekmann F., Waiser J., Fritsche L., Dragun D., Neumayer H.H., and Budde K. Conversion to rapamycin in renal allograft recipients with biopsy proven calcineurin inhibitor induced nephrotoxicity. Transplant Proc 33 (2001) 3234-3235
14. Wyzgal J., Paczek L., Senatorski G., Pilecki T., Gradowska L., Zegarska J., et al. Sirolimus rescue treatment in calcineurin inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 34 (2002) 3185-3187
15. Citterio F., Scata M.C., Violi P., Romagnoli J., Pozzetto U., Nanni G., et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 35 (2003) 1292-1294
16. Diekmann F., Budde K., Oppenheimer F., Fritsche L., Neumayer H.H., and Campistol J.M. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transpl 4 (2004) 1869-1875
17. Jaster R., Bittof T., Klinken S.P., and Brock J. Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin. Biochem Pharmacol 51 (1996) 1181-1185
18. Kaplan M.J., Ellis C.N., Bata Csorgo Z., Kaplan R.S., Endres J.L., and Fox D.A. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch Dermatol 135 (1999) 553-557